Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant

Samer A. Srour, MB ChB, MS, Parth Desai, MD MBBS, Stefan O. Ciurea, Qaiser Bashir, MD MBBS, Betul Oran, MDMS, Amanda L. Olson, MD, Sairah Ahmed, MD, Prithviraj Bose, MD, Rohtesh S. Mehta, MDMPH,MS, Naveen Pemmaraju, MD, Srdan Verstovsek, MD PhD, Richard E Champlin, MD, Uday Popat, MD

Blood (2017) 130 (Supplement 1): 2007.

https://doi.org/10.1182/blood.V130.Suppl_1.2007.2007

Published: 2017

Journal Articles

Analysis of Outcome of Patients with Acute Myeloid Leukemia According to Socio-Economic Status

Namali Pierson, MD, Shawn Chaudry, MPH, Gabriel Vidal, MD, Michael Machiorlatti, MS, Summer Frank, MPH, Sara K. Vesely, PhD, James K. Feisal, MD, Samer A Srour, MB ChB, MS, Mohammad O. Khalil, MD, Alexandra Ikeguchi, MD, Mohamad Khawandanah, MD, Mohamad Cherry, MD

Blood (2015) 126 (23): 5627.

https://doi.org/10.1182/blood.V126.23.5627.5627

Published: 2015

Journal Articles

Incidence and Patient Survival of Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) in the United States: A Population-Based View of the Modern Diagnostic Era

Samer A Srour, MB ChB, MS, Susan S Devesa, MD, Lindsay M Morton, PhD, David P Check, Rochelle E Curtis, MA, Martha S Linet, MD MPH, Graca M Dores, MD MPH

Blood (2015) 126 (23): 2806.

https://doi.org/10.1182/blood.V126.23.2806.2806

Published: 2015

Journal Articles

Impact of Insurance Status on the Day of Admission and Clinical Outcome on Acute Myeloid Leukemia (AML)Patients

Bilal Ahmad, MD, Hossein Maymani, MD, Haseeb Saeed, MD, Mohamad Khawandanah, MD, Samer A Srour, MB ChB, Michael G Machiorlatti, MS, Adam S. Asch, MD, Mohamad Cherry, MD

Blood (2014) 124 (21): 2274.

https://doi.org/10.1182/blood.V124.21.2274.2274

Published: 2014

Journal Articles

Time from Hospital Admission to Induction Chemotherapy Adversely Affects Outcomes in Patients with Acute Myeloid Leukemia

Hossein Maymani, MD, Bilal Ahmad, MD, Michael G Machiorlatti, MS, Sara K. Vesely, PhD, Samer A Srour, MB ChB, George Selby, MD, Adam S. Asch, MD, Mohamad Cherry, MD

Blood (2014) 124 (21): 1289.

https://doi.org/10.1182/blood.V124.21.1289.1289

Published: 2014

Journal Articles

Analysis Of Impact Of Distance From Residence To Treatment Center On The Outcome Of Patients With Acute Myeloid Leukemia

David W. Lam, MD, Hossein Maymani, MD, Michael G Machiorlatti, MS, Samer A Srour, MB ChB, Minh Phan, MD, George Selby, MD, Jennifer L. Holter, MD, Mohamad Cherry, MD

Blood (2013) 122 (21): 1712.

https://doi.org/10.1182/blood.V122.21.1712.1712

Published: 2013

Journal Articles

Erlotinib Is Not Effective In Patients (Pts) With JAK-2 V617F Positive Polycythemia Vera

Mohamad Cherry, MD, Mohamad Khawandanah, MD, Zhizhuang Joe Zhao, Samer A Srour, MB ChB, Howard Ozer, MD, PhD, George Selby, MD, Bassam Ghabache, MD, Aref Al-Kali, MD

Blood (2013) 122 (21): 1597.

https://doi.org/10.1182/blood.V122.21.1597.1597

Published: 2013

Journal Articles

Acute Myeloid Leukemia: Pretreatment Biochemical and Clinical Variables Predictive For Risk Status Based On Validated Cytogenetic and Molecular Abnormalities

Samer A Srour, MB ChB, Michael G Machiorlatti, MS, Mohamad Cherry, MD, Namali Pierson, MD, Usman Z Bhutta, MD, David M Thompson, Ph.D., P.T., Carla D Kurkjian, MD

Blood (2013) 122 (21): 4962.

https://doi.org/10.1182/blood.V122.21.4962.4962

Published: 2013

Journal Articles

Patients with FLT3 Negative Acute Myeloid Leukemia and Normal Cytogenetic who Have the Combination Mutations (NPM1-/CEBPA-) Have Better Survival Than Patients Who Have the Combination Mutations (NPM1+/CEBPA+)

Shamail Butt, MD, Pascal Akl, MD, Himanshu Bhardwaj, MD, Samer A Srour, MB ChB, Terry Dunn, PHD, Shubham Pant, MD, Mohamad Ali Cherry, MD

Blood (2011) 118 (21): 4874.

https://doi.org/10.1182/blood.V118.21.4874.4874

Published: 2011

NARROW

Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant

Analysis of Outcome of Patients with Acute Myeloid Leukemia According to Socio-Economic Status

Incidence and Patient Survival of Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) in the United States: A Population-Based View of the Modern Diagnostic Era

Impact of Insurance Status on the Day of Admission and Clinical Outcome on Acute Myeloid Leukemia (AML)Patients

Time from Hospital Admission to Induction Chemotherapy Adversely Affects Outcomes in Patients with Acute Myeloid Leukemia

Analysis Of Impact Of Distance From Residence To Treatment Center On The Outcome Of Patients With Acute Myeloid Leukemia

Erlotinib Is Not Effective In Patients (Pts) With JAK-2 V617F Positive Polycythemia Vera

Acute Myeloid Leukemia: Pretreatment Biochemical and Clinical Variables Predictive For Risk Status Based On Validated Cytogenetic and Molecular Abnormalities

Patients with FLT3 Negative Acute Myeloid Leukemia and Normal Cytogenetic who Have the Combination Mutations (NPM1-/CEBPA-) Have Better Survival Than Patients Who Have the Combination Mutations (NPM1+/CEBPA+)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only